Welcome to our dedicated page for Werewolf Therapeutics news (Ticker: HOWL), a resource for investors and traders seeking the latest updates and insights on Werewolf Therapeutics stock.
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) is a groundbreaking biopharmaceutical company specializing in the development of innovative cancer treatments. Leveraging its proprietary PREDATOR™ platform, Werewolf Therapeutics is at the forefront of creating conditionally activated therapeutics designed to stimulate the body’s immune system to combat cancer.
Founded with the mission to address the limitations of conventional proinflammatory immune therapies, Werewolf's core offering includes the pioneering INDUKINE™ molecules. These molecules are engineered to remain inactive in peripheral tissues and activate only within the tumor microenvironment (TME), thereby enhancing both adaptive and innate immunity. This strategic approach aims to significantly reduce systemic toxicity while maximizing therapeutic efficacy.
Among its leading developments, the WTX-124 and WTX-330 stand out. WTX-124, an IL-2 INDUKINE molecule, is currently undergoing a Phase 1/1b clinical trial for patients with advanced or metastatic solid tumors. Recent preliminary data presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting highlight WTX-124’s potential, showing it to be well-tolerated and effective even at higher doses. The study demonstrated proof of mechanism and concept with early evidence of monotherapy antitumor activity.
Moreover, Werewolf is exploring the combination of WTX-124 with pembrolizumab (KEYTRUDA®) to expand its therapeutic reach. Another notable candidate, WTX-330, targets both advanced solid tumors and non-Hodgkin lymphoma using IL-12 INDUKINE molecules.
In addition to its clinical advancements, Werewolf Therapeutics has been actively presenting preclinical data supporting the efficacy of its INDUKINE technology. At recent conferences, the company introduced WTX-518, a novel IL-18 INDUKINE molecule, and reported on the preclinical development of IL-10 INDUKINE molecules for treating inflammatory bowel disease.
With a consistent track record of innovation and a robust pipeline of transformative therapies, Werewolf Therapeutics continues to make significant strides towards providing new hope for cancer patients worldwide.
Werewolf Therapeutics (HOWL) presented interim Phase 1 clinical trial results for WTX-330, their tumor-activated IL-12 prodrug, at SITC's 39th Annual Meeting. The trial enrolled 25 patients with diverse solid tumors, showing favorable tolerability and encouraging efficacy. Key findings include a confirmed partial response in a melanoma patient and evidence of tumor immune activation in MSS CRC patients. WTX-330 demonstrated 22-fold greater plasma exposure compared to rhIL-12, with low active IL-12 levels. The company plans to initiate a Phase 1/2 dose-finding trial in H1 2025. Additional preclinical data showed promising results for INDUKINE molecules with various cytokines.
Werewolf Therapeutics (HOWL) reported Q3 2024 financial results and provided updates on its clinical pipeline. The company reported a net loss of $16.7 million with cash and equivalents of $122.8 million, providing runway through Q2 2026. Key developments include ongoing Phase 1/1b trials of WTX-124 and WTX-330, with initial efficacy data expected in H1 2025. The company introduced WTX-921, a new IL-10 INDUKINE molecule for inflammatory diseases. Clinical trials showed promising results, including confirmed partial responses in melanoma patients and a complete response in an advanced CSCC patient that has remained in remission for over twelve months.
Werewolf Therapeutics (Nasdaq: HOWL) has announced WTX-921, a novel IL-10 INDUKINE development candidate for Inflammatory Bowel Disease (IBD) and other inflammatory diseases. This expansion leverages their PREDATOR® platform technology, which has shown promising safety and efficacy in oncology trials. The platform enables conditional activation of cytokines specifically in disease tissues while protecting healthy tissues. WTX-921 represents the company's strategic move beyond oncology into inflammatory diseases, targeting IBD which affects approximately 0.7% of Americans (721 cases per 100,000 people). The development addresses a significant unmet medical need, as IBD currently has no cure, only symptom management options.
Werewolf Therapeutics (Nasdaq: HOWL) announced it will present two posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting in Houston, Texas, from November 6-10, 2024. The first poster, titled 'INDUKINE™ Molecules Delivering Various Cytokines Utilize Unique Mechanisms of Action to Drive Anti-Tumor Efficacy in Murine Syngeneic Tumor Models' (Abstract 955), will be presented on November 8. The second poster, 'The tumor-activated IL-12 prodrug WTX-330 expanded/activated tumor infiltrating lymphocytes and caused tumor regression in patients with refractory solid tumors: Interim data from an ongoing Ph1 study' (Abstract 672), will be presented on November 9.
Both presentations will take place at the George R. Brown Convention Center - Exhibit Halls A B. Werewolf Therapeutics is a biopharmaceutical company focused on developing conditionally activated therapeutics to stimulate the immune system for cancer treatment.
Werewolf Therapeutics (Nasdaq: HOWL), a biopharmaceutical company developing conditionally activated therapeutics for cancer treatment, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York City.
Key details:
- Daniel J. Hicklin, Ph.D., President and CEO, and Randi Isaacs, M.D., Chief Medical Officer, will participate in a fireside chat
- The presentation is set for September 10, 2024, at 11:00 am ET
- A webcast link will be available on the company's investor relations website
- An archived replay will be accessible for approximately 90 days after the event
This conference provides Werewolf Therapeutics an opportunity to showcase its innovative approach to cancer immunotherapy and engage with potential investors.
Werewolf Therapeutics (Nasdaq: HOWL) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Positive data from WTX-124 Phase 1/1b trial presented at ASCO, showing clinical activity and tolerability.
2. Encouraging signs of clinical activity for WTX-330 Phase 1 trial at tolerable doses.
3. Cash position of $135.3 million as of June 30, 2024, expected to fund operations through Q1 2026.
4. Q2 2024 net loss of $17.2 million, compared to $5.1 million in Q2 2023.
5. Collaboration revenue decreased to $1.1 million in Q2 2024 from $8.1 million in Q2 2023.
6. R&D expenses increased to $15.3 million in Q2 2024 from $9.6 million in Q2 2023.
Werewolf Therapeutics reveals initial safety and efficacy data from its ongoing Phase 1 clinical trial of WTX-330. The trial involves patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma. The data show WTX-330 achieved therapeutically relevant exposure levels of IL-12 prodrug with improved tolerability compared to historical data. One metastatic melanoma patient showed an unconfirmed partial response, and two colorectal cancer patients achieved stable disease. Mild to moderate treatment-related toxicities were observed, with no Grade 4 or 5 adverse events. An expanded Phase 1 program is now open, with further results anticipated in Q4 2024.
Werewolf Therapeutics has announced new data from their Phase 1/1b trial of WTX-124, an IL-2 INDUKINETM molecule, in patients with solid tumors. The data, presented at ASCO 2024, highlight WTX-124's clinical activity and tolerability, both as a monotherapy and in combination with pembrolizumab. Three objective responses were noted, including one complete response, and the treatment was generally well-tolerated. The company has selected an 18 mg dose of WTX-124 monotherapy for expansion and opened three new trial arms. Additionally, WTX-124 showed enhanced immune activation in combination with pembrolizumab. A webcast to discuss these findings will be held on June 3, 2024.
Werewolf Therapeutics, an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics to stimulate the body's immune system for cancer treatment, announced its participation at the Jefferies Global Healthcare Conference.
Daniel J. Hicklin, Ph.D., President and CEO, and Randi Isaacs, M.D., Chief Medical Officer, will join a fireside chat at 1:00 PM ET on June 6, 2024. The conference will be held from June 4-6 in New York City.
A live webcast link for the event will be available on Werewolf's investor relations webpage, with an archived replay accessible for 90 days post-event.
Werewolf Therapeutics announced the presentation of updated clinical data from its Phase 1/1b trial of WTX-124, both as monotherapy and in combination with pembrolizumab, at the 2024 ASCO Annual Meeting. The data, current as of January 28, 2024, and updated until May 1, 2024, shows that WTX-124 is well-tolerated and clinically active in patients with advanced or metastatic solid tumors who have relapsed after checkpoint inhibitor therapy.
Preliminary combination data with pembrolizumab indicates similar tolerability to monotherapy. Werewolf will host a webcast on June 3, 2024, to discuss the results in detail. This Phase 1/1b trial is evaluating the IL-2 INDUKINE™ molecule, aiming to address unmet medical needs in difficult-to-treat cancers.
FAQ
What is the current stock price of Werewolf Therapeutics (HOWL)?
What is the market cap of Werewolf Therapeutics (HOWL)?
What does Werewolf Therapeutics specialize in?
What is the PREDATOR™ platform?
What are INDUKINE™ molecules?
What is WTX-124?
Are there other key product candidates from Werewolf?
What recent advancements has Werewolf made?
How does Werewolf's approach differ from conventional therapies?
Is Werewolf involved in any partnerships or collaborations?
What is the significance of the recent WTX-124 clinical data?
How can investors stay informed about Werewolf's progress?
